Navigation Links
Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
Date:10/4/2007

here appears to be limited systemic exposure. Its short duration of systemic exposure (hours) relative to the long duration of analgesia (weeks to months) resulting from a single treatment of Adlea is particularly important in this typically elderly and vulnerable patient population and may also potentially offer a safer treatment option in the management of chronic osteoarthritis pain. Importantly, the prolonged analgesic effect resulting from a single or stepped dose, localized administration of Adlea does not seem to be associated with the systemic side effects commonly associated with NSAIDs (gastrointestinal and renal toxicities, and impaired clotting), COX-2 inhibitors (cardiovascular risks and renal toxicity), or opiates (respiratory depression, nausea/vomiting, sedation, disorientation, physical dependence, and the risk of addiction). In clinical studies to date, Adlea has been shown to be well tolerated.

About Total Hip Replacement

Total hip replacement is performed in patients with late-stage degenerative hip disease. A number of conditions and diseases can cause the cartilage surfaces of the hip joint's ball-and-socket components to degenerate, which leads to pain, stiffness, and disability. According to the American Academy of Orthopedic Surgeons, more than 193,000 total hip replacements are performed each year in the United States, and this number will increase by an estimated 174 percent to 572,000 by the year 2030.

About Anesiva and its Diverse Portfolio of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has one FDA-approved product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, to reduce pain associated with peripheral venous access procedures in children three to 18 years of age. The second product in Anesiva's pipeline, Adlea(TM) (formerly 4975
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... LONDON , Sept. 1, 2014 ... Brazil Aesthetic Lasers and Energy ... https://www.reportbuyer.com/product/2343455/Brazil-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html Brazil Aesthetic ... Summary GlobalData,s new ... Outlook to 2020", provides key market data on ...
(Date:9/1/2014)... Sept. 1, 2014 ... is available in its catalogue: Antibody ... http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... new class of therapeutic agents, gaining increasing attention ... addressed as the marriage of an antibody with ...
(Date:9/1/2014)... YORK , Sept. 1, 2014 ... is available in its catalogue:  Drug Discovery ... http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html The ... such as cancer requires extensive expenditure, in addition ... step in designing a new drug involves the ...
Breaking Medicine Technology:Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11
... 10, 2010 /PRNewswire-FirstCall/ -- HealthWarehouse.com, Inc ... leading VIPPS accredited retail mail-order pharmacy, announced today that ... equity and convertible debt with independent investors. ... company,s online presence while upgrading its technology infrastructure to ...
... 10, 2010 Nycomed US Inc. announced today the ... Vice President and General Counsel, reporting to Steve Andrzejewski, ... legal advisor of the company and oversee all of ... he will also be responsible for the company,s compliance ...
Cached Medicine Technology:HealthWarehouse.com Places $3.3 Million in Preferred Stock and $1 Million in Convertible Debt 2HealthWarehouse.com Places $3.3 Million in Preferred Stock and $1 Million in Convertible Debt 3Joseph J. LaRosa Joins Nycomed US Inc. 2
(Date:9/1/2014)... 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) ... major markets (the US, France, Italy, Germany, Spain and ... billion by 2018. , The competitive landscape in the ... Spain and the UK is poised to undergo a ... the four largest B-cell NHL indications, which includes Diffuse ...
(Date:9/1/2014)... 1 September 2014: Daily fruit consumption cuts the risk ... to research presented at ESC Congress today by Dr ... seven year follow-up study of nearly 0.5 million people ... fruit people ate, the more their risk of CVD ... disease (IHD) and stroke, is the leading cause of ...
(Date:9/1/2014)... 01, 2014 As well as having ... is currently pursuing counselor certification in Louisiana. ... the CPI training program as well as the ... grown both personally and professionally. I am not ... competently able to do so. As a Non ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 BCC Research ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , the ... million in 2013 and is expected to reach $38.7 ... to $471.5 million by 2019, which is equivalent to ... 2019. The receptor-mediated transport (RMT) segment is forecasted to ...
(Date:9/1/2014)... In honor of National Take Your Cat to the Vet Day, ... of Minnesota (AERC) is offering a few reasons why pet owners ... people don’t take their cat to the vet because “there’s nothing ... decide not to take their kid to dentist because he or ... pets. Just like people want their loved ones to be healthy, ...
Breaking Medicine News(10 mins):Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3
... A 29-year-old Indonesian man has died of bird flu, bringing ... to 80, the world's highest, an official said Friday. ... in hospital Tuesday in Pekanbaru, capital of Riau province on ... at the Indonesian health ministry. ,"He had a ...
... been transferred back to the LA prison where she is ... medical ward. ,Jail authorities said that the hotel ... Towers Correctional Facility for less than a week. ... jail sentence for violating terms of probation, was taken to ...
... getting some extra sleep before a big game could ... ,Researcher Cheri Mah and colleagues at Stanford University observed ... ,They were told to maintain their usual sleeping habits ... they were instructed to get as much extra sleep ...
... over the legislation aimed at preventing discrimination of the HIV ... ,Union Health Minister Anbumani Ramadoss said that the HIV/AIDS bill ... with the NGOs on the issue that could guarantee safe-working ... ,The bill also provides for access to treatment ...
... identified by Yale School of Medicine researcher Michael Kozal, ... quickly detects rare viral mutations. ,Kozal, associate ... the retrospective study that used samples from an earlier ... International HIV Drug Resistance Workshop in Barbados. ...
... thought a toilet could save her so much time and money. ... shack in Kibera, Africa's largest slum, she realized it could. ... installed the latrine that uses human waste to produce gas to ... dwellers. ,"At first I thought it was a very ...
Cached Medicine News:Health News:Bill on HIV/AIDS Delayed Further 2Health News:HIV Drug Resistance can Be Identified by Genome Sequencing 2Health News:Bio-latrine Cleans Up Kenyan Slum and the Environment 2Health News:Bio-latrine Cleans Up Kenyan Slum and the Environment 3
The Thermal pads were designed to simulate water immersion, the most effective method of transferring energy non-invasively....
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Medicine Products: